Show simple item record

The EMPOWER blended digital intervention for relapse prevention in schizophrenia : a feasibility cluster randomised controlled trial in Scotland and Australia

dc.contributor.authorGumley, Andrew I.
dc.contributor.authorBradstreet, Simon
dc.contributor.authorAinsworth, John
dc.contributor.authorAllan, Stephanie
dc.contributor.authorAlvarez-Jimenez, Mario
dc.contributor.authorAucott, Lorna
dc.contributor.authorBirchwood, Maximillian
dc.contributor.authorBriggs, Andrew
dc.contributor.authorBucci, Sandra
dc.contributor.authorCotton, Sue M.
dc.contributor.authorEngel, Lidia
dc.contributor.authorFrench, Paul
dc.contributor.authorLederman, Reeva
dc.contributor.authorLewis, Shôn
dc.contributor.authorMachin, Matthew
dc.contributor.authorMacLennan, Graeme
dc.contributor.authorMcLeod, Hamish
dc.contributor.authorMcMeekin, Nicola
dc.contributor.authorMihalopoulos, Cathy
dc.contributor.authorMorton, Emma
dc.contributor.authorNorrie, John
dc.contributor.authorSchwannauer, Matthias
dc.contributor.authorSingh, Swaran P.
dc.contributor.authorSundram, Suresh
dc.contributor.authorThompson, Andrew
dc.contributor.authorWilliams, Chris
dc.contributor.authorYung, Alison R.
dc.contributor.authorFarhall, John
dc.contributor.authorGleeson, John
dc.date.accessioned2023-07-05T23:08:58Z
dc.date.available2023-07-05T23:08:58Z
dc.date.issued2022-06
dc.identifier221983131
dc.identifier08ba5cd7-55b8-4c92-bac6-bd1177fad078
dc.identifier85129950487
dc.identifier35569503
dc.identifier.citationGumley , A I , Bradstreet , S , Ainsworth , J , Allan , S , Alvarez-Jimenez , M , Aucott , L , Birchwood , M , Briggs , A , Bucci , S , Cotton , S M , Engel , L , French , P , Lederman , R , Lewis , S , Machin , M , MacLennan , G , McLeod , H , McMeekin , N , Mihalopoulos , C , Morton , E , Norrie , J , Schwannauer , M , Singh , S P , Sundram , S , Thompson , A , Williams , C , Yung , A R , Farhall , J & Gleeson , J 2022 , ' The EMPOWER blended digital intervention for relapse prevention in schizophrenia : a feasibility cluster randomised controlled trial in Scotland and Australia ' , The Lancet Psychiatry , vol. 9 , no. 6 , pp. 477-486 . https://doi.org/10.1016/S2215-0366(22)00103-1en
dc.identifier.issn2215-0366
dc.identifier.otherORCID: /0000-0002-1039-5646/work/123847386
dc.identifier.otherORCID: /0000-0001-6277-7972/work/123847951
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19632
dc.descriptionFunding Information: AIG reports personal fees from University of Manchester, personal fees from University of Exeter, personal fees from British Association for Behavioural and Cognitive Psychotherapies and other interests with UK National Health Service (NHS) Education for Scotland outside the submitted work. JA, SL, and SB report other interests with CareLoop Health, outside the submitted work. SB reports grants from the Medical Research Council and UK National Institute for Health Research (NIHR) during the conduct of the study. SL reports grants from the UK Medical Research Council (MRC) during the conduct of the study. JA reports grants from MRC, Engineering and Physical Sciences Research Council, Economic and Social Research Council, NIHR, and the US National Institute for Health, and was a Fellow of the Alan Turing Institute during the conduct of the study. AB reports personal fees from Bayer, Merck, Janssen, Novartis, Sword Health, Amgen, and Daiichi Sankyo outside the submitted work. JF reports grants from National Health and Medical Research Council (Australia) during the conduct of the study and other interests with Melbourne Health (NorthWestern Mental Health) outside the submitted work. HMcL reports grants from NIHR Health Technology Assessment (HTA) during the conduct of the study, and grants with Academy of Medical Sciences, Glasgow Children's Hospital Charity, and Scotland's Chief Scientist's Office. CM reports grants from National Health and Medical Research Council (Australia) during the conduct of the study. JN reports grants from the University of Aberdeen and the University of Edinburgh during the conduct of the study and declares membership of the following NIHR boards: Cardio Pulmonary Resusitation decision making committee; HTA commissioning board; HTA commissioning sub-board (expression of interest); HTA funding boards policy group; HTA general board; HTA post-board funding teleconference; NIHR clinical trials unit standing advisory committee; NIHR HTA and Efficacy Mechanism Evaluation editorial board; pre-exposure prophylaxis impact review panel. PF is a member of the HTA mental health prioritisation panel. CW reports grants from NIHR during the conduct of the study and from the Royal College of Psychiatrists, and other interests with Five Areas outside the submitted work. AY reports an NIHR Senior Investigator Grant. JG reports grants from the National Health Medical Research Council. All other authors declare no competing interests. Funding Information: This project was funded in the UK by the NIHR-HTA programme (project number 13/154/04) and in Australia by the National Heath and Medical Research Council (APP1095879). The research will be published in full in the HTA. This study is supported by NHS Research Scotland, through the Chief Scientist Office and the NHS Scotland Mental Health Network. The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health Directorate. MA-J is supported by an Investigator Grant (APP1177235) from the National Health and Medical Research Council and a Dame Kate Campbell Fellowship from The University of Melbourne. MB and SS are supported by NIHR Applied Research Centre (ARC) West Midlands. SA is supported by a Cremore Research Fellowship, donated to the University of Glasgow. This independent research study was funded by the UK NIHR-HTA. The views expressed in this publication are those of the authors and not necessarily of the NHS, the National Institute for Health Research, or the UK Department of Health and Social Care. The study sponsors and funders were not involved in the study design; collection, management, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication. We would like to thank health and care providers in Scotland and Australia who contributed to the study and of course to all the service users and their supporters who participated in this research. We sincerely hope we have met your expectations in taking part. We would like to acknowledge and recognise the contribution of members of the research team not listed as authors. These include Imogen Bell, Emily Castagnini, Andrea Clark, Amy Hood, Maria Lambrou, Casey Lynch, Casey McCrae, Ishani Majmudar, Claire Matrunola, Giada Micolucci, Sophie Norman, Lesley Smith, Suzy Syrett, David Thomson, Helen Whitehill, and Alison Wilson Kay. We also express our gratitude to our Study Steering Committee members: Prof David Kingdon (Chair), Prof Daniel Freeman (independent member), Prof Fiona Lobban (independent member), David Kavanagh (independent member), and Graham Morgan (Independent Public and Patient Involvement Representative). We also express our gratitude to our Data Monitoring and Ethics Committee members: Prof Emmanuelle Peters (Chair), Dr Alison Brabban (Independent Clinician), Prof Rod Taylor (Independent Statistician), and Prof Greg Murray (Independent Statistician). Funding Information: This project was funded in the UK by the NIHR-HTA programme (project number 13/154/04) and in Australia by the National Heath and Medical Research Council (APP1095879). The research will be published in full in the HTA. This study is supported by NHS Research Scotland, through the Chief Scientist Office and the NHS Scotland Mental Health Network. The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health Directorate. MA-J is supported by an Investigator Grant (APP1177235) from the National Health and Medical Research Council and a Dame Kate Campbell Fellowship from The University of Melbourne. MB and SS are supported by NIHR Applied Research Centre (ARC) West Midlands. SA is supported by a Cremore Research Fellowship, donated to the University of Glasgow. This independent research study was funded by the UK NIHR-HTA. The views expressed in this publication are those of the authors and not necessarily of the NHS, the National Institute for Health Research, or the UK Department of Health and Social Care. The study sponsors and funders were not involved in the study design; collection, management, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication. We would like to thank health and care providers in Scotland and Australia who contributed to the study and of course to all the service users and their supporters who participated in this research. We sincerely hope we have met your expectations in taking part. We would like to acknowledge and recognise the contribution of members of the research team not listed as authors. These include Imogen Bell, Emily Castagnini, Andrea Clark, Amy Hood, Maria Lambrou, Casey Lynch, Casey McCrae, Ishani Majmudar, Claire Matrunola, Giada Micolucci, Sophie Norman, Lesley Smith, Suzy Syrett, David Thomson, Helen Whitehill, and Alison Wilson Kay. We also express our gratitude to our Study Steering Committee members: Prof David Kingdon (Chair), Prof Daniel Freeman (independent member), Prof Fiona Lobban (independent member), David Kavanagh (independent member), and Graham Morgan (Independent Public and Patient Involvement Representative). We also express our gratitude to our Data Monitoring and Ethics Committee members: Prof Emmanuelle Peters (Chair), Dr Alison Brabban (Independent Clinician), Prof Rod Taylor (Independent Statistician), and Prof Greg Murray (Independent Statistician). Publisher Copyright: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 licenseen
dc.format.extent10
dc.format.extent415752
dc.language.isoeng
dc.relation.ispartofThe Lancet Psychiatryen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectPsychiatry and Mental healthen
dc.subjectBiological Psychiatryen
dc.subject.lccRC0321en
dc.titleThe EMPOWER blended digital intervention for relapse prevention in schizophrenia : a feasibility cluster randomised controlled trial in Scotland and Australiaen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Centre for Health Data Scienceen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1016/S2215-0366(22)00103-1
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85129950487&partnerID=8YFLogxKen
dc.identifier.vol9en
dc.identifier.iss6en


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record